Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03013712 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer(CARTEPC) | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT02987244 | Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 8, 2016 |
| clinicaltrials |
| NCT02617134 | CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02892695 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02944162 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02983942 | Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Beijing Tiantan HospitalOTHER | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02980315 | A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application | unknown | Phase 1 / Phase 2 | 20 | The Second Hospital of Nanjing Medical UniversityOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT02274337 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02970786 | Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans | unknown | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Nov 22, 2016 | clinicaltrials |
| NCT02968472 | A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia | unknown | Phase 1 | 30 | The First People's Hospital of YunnanOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02965157 | Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma | unknown | Phase 1 / Phase 2 | 15 | Beijing Biohealthcare Biotechnology Co.,LtdINDUSTRY | 1 | Nov 16, 2016 | clinicaltrials |
| NCT02959151 | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy | unknown | Phase 1 / Phase 2 | 20 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT02721784 | Serial mpMRI (Multi Parametric Magnetic Resonance Imaging) Scanning in Prostate Cancer After Androgen Deprivation Therapy and RadioTherapy(SMART) | unknown | Phase 1 / Phase 2 | 10 | University College, LondonOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02939378 | Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study(KGDinrGBM) | unknown | Phase 1 / Phase 2 | 60 | Song LinOTHER | 1 | Oct 20, 2016 | clinicaltrials |
| NCT02937844 | Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme | unknown | Phase 1 | 20 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT02810223 | Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Beijing Sanwater Biological Technology Co., Ltd.INDUSTRY | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02933775 | CD19-redirected Autologous Cells (CAR-CD19 T Cells) | unknown | Phase 1 | 45 | RenJi HospitalOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02903810 | Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy | unknown | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT01600573 | Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) | unknown | Phase 1 / Phase 2 | 68 | JSehouliOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT02873416 | Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02873442 | Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02873520 | Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT00906113 | Intra-arterial Chemotherapy for Children With Retinoblastoma | unknown | Phase 1 / Phase 2 | 10 | Hadassah Medical OrganizationOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT02568241 | Interferon-α After DLI for the Prevention of Relapse(IDPR-HSCT) | unknown | Phase 1 / Phase 2 | 42 | Peking University People's HospitalOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | unknown | Phase 1 / Phase 2 | 31 | NovoCure Ltd.INDUSTRY | 4 | Sep 21, 2016 | clinicaltrials |
| NCT02906163 | First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy | unknown | Phase 1 / Phase 2 | 188 | SciClone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01952769 | Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma | unknown | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT02895412 | Infection and Tumour Antigen Cellular Therapy(INTACT-WT1) | unknown | Phase 1 | 20 | University of SydneyOTHER | 1 | Sep 9, 2016 | clinicaltrials |
| NCT02151071 | The Breast Surgery EnLight and LightPath Imaging System Study | unknown | Phase 1 / Phase 2 | 30 | Lightpoint Medical LimitedINDUSTRY | 1 | Sep 7, 2016 | clinicaltrials |
| NCT02737085 | the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) | unknown | Phase 1 / Phase 2 | 40 | Southwest Hospital, ChinaOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT02888418 | Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17 | unknown | Phase 1 | 135 | Beijing Chaoyang District Centre for Disease Control and PreventionOTHER | 0 | Sep 5, 2016 | clinicaltrials |
| NCT02862587 | Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 40 | Shanghai International Medical CenterINDUSTRY | 1 | Sep 2, 2016 | clinicaltrials |
| NCT02862613 | Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 40 | Shanghai International Medical CenterINDUSTRY | 1 | Sep 2, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT01758367 | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02882659 | Dendritic Killer Cell-based Immunotherapy for Solid Tumors | unknown | Phase 1 | 18 | FullHope Biomedical Co., Ltd.INDUSTRY | 0 | Aug 30, 2016 | clinicaltrials |
| NCT02876978 | Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma | unknown | Phase 1 | 20 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT02856685 | A Study of Mitoxantrone Hydrochloride Liposome Infusion | unknown | Phase 1 / Phase 2 | 60 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 22, 2016 | clinicaltrials |
| NCT02859948 | A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 9, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT01146262 | Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)(CD lam) | unknown | Phase 1 / Phase 2 | 5 | Nantes University HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02844062 | Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme | unknown | Phase 1 | 20 | Beijing Sanbo Brain HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02399735 | Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation | unknown | Phase 1 | 18 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT02840617 | ICG-based Fluorescence Imaging in Localization of Prostate Cancer and Metastatic Lymph Nodes | unknown | Phase 1 | 50 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Jan 6, 2017source: clinicaltrials